The evolution of Lyme borreliosis in transgenic mice tolerant to Borrelia Clin. Invest. 1995. 95:1706-1714 
Introduction
Borrelia burgdorferi, a spirochete, causes Lyme disease-the most common vector-borne infection in the United States (1) (2) (3) . Infection in man can result in a skin lesion, erythema migrans, and sometimes progress to cause disease involving the heart, joints and nervous system (2, 3) . In most cases, the symptoms resolve but occasional exacerbations of disease may occur (2) . Lyme borreliosis in inbred C3H/HeJ (C3H) mice partially mimics the human illness. C3H mice challenged with B. burgdorferi N40 develop a disseminated infection with spirochetemia, arthritis and carditis that is most severe at 2-4 wk (4, 5) . At these time points the inflammatory response is marked by a synovial exudate with fibrinoid necrosis and a neutrophilic infiltrate (5) . Over a period of several months the disease progresses to a lymphoplasmacytic infiltrate and then diminishes, -usually by 6 mo, after which time only residual scar tissue is evident in the joints and heart (5, 6) . Rarely, exacerbations of acute inflammatory arthritis, in association with recurrent spirochetemia, can occur in the chronically infected mouse (5) . Although the disease manifestations of Lyme borreliosis in the C3H mouse are mostly transient, the animals remain persistently infected and B. burgdorferi can be cultured from selected murine tissue from 5 d to over 1 year after the initial infection (5, 6) . The course of Lyme borreliosis in humans and mice has been clearly described; however, the factors contributing to the pathogenesis of disease are likely to be multifactorial and remain to be determined.
The pathogenesis of Lyme arthritis is partially influenced by the host's genetic background and ability to clear the spirochete infection. Steere and his colleagues showed that the presence of the HLA-DR4 allele and high antibody titers or cellular immune responses to OspA or B in patients correlated with an increased susceptibility of developing chronic arthritis that is resistant to antibiotic therapy (7) (8) (9) . These studies have led to the proposal that the immune response to OspA may be directly involved in the pathogenesis of disease. Moreover, Peltz and his associates identified Thi T cell clones that responded to OspA in Lyme arthritis synovial fluid and postulated that the cellular immune response to OspA contributes to the genesis of disease (10, 11 ). Peltz's group then further demonstrated that cellular reactivity to diverse epitopes of OspA, and expansion of the Vf5 T cell population, is evident in patients with Lyme arthritis (12, 13) , While these studies suggest that OspA or B specific immune reactivity is associated with the development of arthritis, a cause and effect relationship between an OspA or B response and disease has not been established. These data lead to the hypothesis that the ablation of the host's ability to respond to OspA or B would lead to a reduction in the severity of arthritis.
Inbred strains of mice also develop varying degrees of arthritis following infection with B. burgdorferi-further suggesting that genetically determined host susceptibility contributes to disease. Schaible and his colleagues showed that mice of the H-2k haplotype are more susceptible to clinically evident Lyme arthritis than mice with the H-2d allele, and postulated that a cellular immune response to B. burgdorferi antigens causes disease (14) . Barthold also showed that C3H mice (H-2k) infected with B. burgdorferi developed severe acute arthritis-by histopathologic examination of the joints-that regressed over a period of 1 to 2 mo whereas B6 mice (H-2b) developed less pronounced disease that followed a similar time course (4) . Furthermore, Weis and her associates have shown that the severity of arthritis in inbred mice is partially accounted for by a greater number of spirochetes in the joints of the animals with marked disease (15) . These studies all suggest that the major histocompatibility complex (MHC) haplotype contributes to the genesis of disease and that arthritis may be related to an antigenspecific immune response to B. burgdoiferi, to the quantity of spirochetes in the infected host, or both. In contrast to these murine models of acute regressing arthritis, C.B. 17 severe combined immunodeficient (scid) mice develop persistent unremitting arthritis suggesting, first, that a protective immune response is important in the regression phase of disease and, second, that a B. burgdorferi specific response is not necessary for the genesis of Lyme disease in scid mice (16, 17) .
We, and others, showed that immunization of mice with OspA elicits a protective immune response (18, 19) . Humoral immunity was sufficient for protection as passive immunization with OspA antibodies also prevented infection in both immunocompetent and immunodeficient mice (18, 20) . Vaccination with OspB or C can also elicit partially protective immunity; however, the effects are less pronounced than with OspA (21) (22) (23) (Fig. 1) . ospA or B were cloned into pH-2K to create the OspA plasmid construct used for injection into mouse embryo (Fig. 1) . ospA or B from B. burgdorferi N40 was amplified using the polymerase chain reaction (PCR). 10 ng of a pGEX-2T based plasmid containing ospA or B was used as the template ( 18, 22 arthritis, and (B6 x CBA)F2 mice can be used to generate animals that are predominantly B6 (relatively resistant to B. burgdorferi induced arthritis) by selective breeding. By using these two strains of inbred mice we could then determine the effects of OspA or B tolerance on disease pathogenesis in mice that develop different degrees of arthritis. To prepare the DNA for microinjection into mouse embryos, the recombinant plasmids were purified by double-banding the plasmids over a CsCl gradient by equilibrium centrifugation. The EcoRI fragment of plasmid DNA was linearized by partial digestion with EcoRI. The 10-kb fragment was isolated on an agarose gel, purified, concentrated using an Elutip-d column and dialyzed into a buffer suitable for microinjection of DNA into murine blastocysts (0.01 M Tris pH 7.4, 0.OOOlM EDTA, and pyrogen free water). The micro-injected embryos were implanted into pseudo-pregnant females and newborn mice were analyzed for the presence of ospA or B by Southern blotting. DNA was isolated by digestion of mouse tail specimens with proteinase K overnight at room temperature, and then purified by phenol chloroform extraction. 10 mig of the recovered DNA was used for further analysis. Slot blots were performed on the isolated DNA using a 32p labeled ospA or B probe. The ospA or B probes contained the entire ospA or B sequences and were labeled using the random Prime-It kit (Stratagene, La Jolla, CA). Specific transgenic lines in B6 mice were expanded by the selective breeding of the (B6 x CBA)F2 founder mice with B6 mice for six generations. When necessary, as was the case with OspB, (B6 x CBA)F2 founder mice were backcrossed with C3H partners for six generations to create OspB transgenic mice that were predominantly of the C3H strain.
B. burgdorferi. Cloned B. burgdorferi N40 with proven pathogenicity in mice were cultured in Barbour-Stoenner-Kelly II (BSK II) media (24) . The concentration of organisms was adjusted to 1 X 105 or 1 x 108 spirochetes per ml. Mice were inoculated with 1 X I04 or 1 x 10' organisms in 100 IL of BSK II media intradermally.
ELISA. B. burgdorferi N40 whole cell lysates or recombinant OspA or B was used as the substrate for ELISA (27 24, 27) . Proteins were transferred to nitrocellulose paper and the resulting strips were blocked in 5% bovine serum albumin (BSA) for 90 min and then incubated with murine serum (1:1,000 dilution) in 5% BSA for 1 h. The strips were washed three times with PBS and bound antibody was detected by incubation with goat anti-mouse IgG or IgM secondary antibody-conjugated to horseradish peroxidase using the enhanced chemiluminescence immunoblotting detection system (Amersham, Arlington Heights, IL).
Immunization studies. To determine functional immune tolerance to OspA we measured OspA antibodies in OspA transgenic mice immunized with recombinant OspA in complete Freund's adjuvant (CFA). Identical studies were performed using OspB transgenic mice and OspB as the immunizing antigen. Since ospA or B in the transgenic mice did not contain the osp leader sequences, the amino acids that correspond to these regions were not included in the recombinant OspA or B used for immunization. The OspA from B. burgdorferi N40 used for immunization was prepared as a nonlipidated antigen and purified in a fashion identical to the work of J. Dunn (28) . The OspB immunogen was prepared as a glutathione transferase fusion protein in which the OspB leader sequence (aa 1-16) was not included. OspB was cleaved from the glutathione transferase fusion partner using thrombin, which acts at a thrombin cleavage site engineered into the construct (22 (21) . Mice were killed from 14 to 180 d after infection. Joints (both knees and tibiotarsi) and hearts were formalin fixed, paraffin embedded, sectioned and blindly examined microscopically for evidence of inflammation, as previously described (29) . Arthritis was blindly graded on a scale from 0 to 3. Grade 0 represented the lack of inflammation, grades 1 and 2 indicated mild to moderate inflammation and grade 3 signified severe inflammation. Active arthritis was scored, tabulated and distinguished as acute (active) or chronic (inactive). Active arthritis was marked by exudation of fibrin and neutrophils into the joints, tendons and ligament sheaths, and hypertrophy and hyperplasia of the synovium. The grade of arthritis was based upon the extent of the observed inflammatory changes. Resolving lesions, with focal lymphoplasmacytic infiltration and synovial scarring, but without active exudation were categorized as chronic, inactive, lesions. Carditis was active when there was acute neutrophilic arteritis of the aortic adventitia and chronic when there was lymphoplasmacytic infiltration of the aorta and connective tissue of the heart base. Blood, spleen, and bladder were collected from the mice, cultured in BSK II medium, incubated for 2 wk, and examined by darkfield microscopy for spirochetes. Twenty high power fields were scanned per culture and the presence of 1 or more B. burgdorferi was considered positive.
Northern blot. Northern blot analysis was performed on mRNA isolated from selected murine tissue from the transgenic mice using the FastTrack mRNA isolation kit (Invitrogen, San Diego, CA). Spleen, liver, thymus, kidney, brain, and lung (1 gram) were removed immediately upon sacrifice and cut into small pieces (0.5 cm). 15 mi of lysis buffer (5 M guanidinium isothiocyanate, 0.05 M Tris-HCl pH 7.5, 0.01 M Na2EDTA, 5% ,B-mercaptoethanol) was added to each tissue specimen and homogenized. The the control of the MHC class I promoter. Transgenic mice were generated on an inbred C3H or (B6 X CBA)F2 background and subsequently backcrossed using B6 or C3H partners so that the influence of tolerance to OspA or B could be assessed in mice that develop severe (C3H) or mild (B6) arthritis. Two founder lines of OspA or B transgenic mice, respectively, were created using (B6 X CBA)F2 embryos. The four founders were backcrossed for six generations using B6 partners to obtain mice that were on a predominantly B6 background. OspB founder mouse No. 1 was also backcrossed for six generations with C3H partners to generate an OspB transgenic mouse that was predominantly C3H. As expected, all mice backcrossed using B6 partners expressed the H-2b haplotype, and mice backcrossed using C3H partners expressed the H-2 k allele. One OspA transgenic founder was created directly from C3H embryos. These mice were then used in infection studies to assess the effect of the transgene on the evolution of Lyme borreliosis in mice that develop severe (C3H) or mild (B6) disease. All the mice were viable, healthy, free of disease, and fertile.
To determine if the mice expressed the incorporated transgene, Northern blot analyses were performed on mRNA isolated from selected tissue from 3-wk-old OspA transgenic mice. RNA from the spleen, liver, thymus, lung, heart and brain were probed with 32p labeled ospA DNA. mRNA expressing the ospA transgene was detected in the spleen, thymus, liver, .and kidney, as a band slightly > 2 kb. By far, the largest amount of ospA was evident in the spleen (Fig. 2) (Fig. 3 A) . Non Fig. 4 C, recombinant OspA migrates at a lower molecular mass than native OspA because of removal of the OspA leader sequence during preparation, resulting in a lack of lipidation). In contrast, the OspA transgenic mice did not develop significant detectable levels of OspA antibodies (Fig. 3 A) . It is likely that the low levels of antibody identified by ELISA (Fig. 3 A) at the later time points in some of the OspA transgenic mice immunized with OspA represented antibodies to E. coli products that were retained with the recombinant OspA during protein purification because sera from immunized mice showed reactivity to a lysate of E. coli but not to purified recombinant OspA in immunoblot (Fig. 4 A) . The tolerance observed was specific for OspA as the OspA transgenic mice developed antibodies to OspB, both in the recombinant and native form, after immunization with recombinant OspB (Fig. 4 B) . Reactivity with recombinant OspB was more obvious because of an increased amount of OspB antigen present on the immunoblot, rather than the level of native antigen in B. burgdorferi lysates. Recombinant OspB has a lower molecular mass than native OspB because of the removal of the OspB leader sequence resulting in a lack of lipidation. In addition, the antibody titers to whole cell lysates of B. burgdorferi by ELISA was similar in OspA transgenic mice and nontransgenic littermates (controls) immunized with 10 Mg of heat-killed spirochetes in CFA-in both cases, antibodies to B. burgdorferi were detectable at a serum dilution of 1:100,000.
Similar studies were performed with the OspB-transgenic mice generated on both a C3H or B6 background. The OspB transgenic mice were immunized with recombinant OspB, in an identical fashion as the OspA transgenic mice that had been immunized with OspA. OspB transgenic mice did not make antibodies to OspB, as detected by ELISA, whereas the control mice had high levels of OspB antibodies (Fig. 3 B) . Moreover, analogous to the studies with OspA, some of the low levels of antibodies generated after immunizing the OspB transgenic mice with OspB may have been directed toward residual E. coli products retained during the purification of OspB. Tolerance was specific for OspB, as the OspB transgenic mice developed antibodies to OspA, both in the native and recombinant form, following immunization with OspA (Fig. 4 D) chetes from blood, spleen and bladders from OspA transgenic mice (89%) and control mice (90%) was similar throughout the course of infection.
To determine if the challenge inoculation of spirochetes could affect the course of disease, the mice were also challenged with a large dose of B. burgdorferi (107). The evolution of disease was similar in both the control and experimental transgenic mice challenged with this number of organisms.
The evolution of Lyme borreliosis in OspA transgenic C3H mice, an inbred strain that is highly susceptible to the development of severe arthritis was also examined. As expected, C3H mice developed more pronounced arthritis that B6 mice, with moderate inflammatory arthritis (severity score of 1.7+±0.4 to 1.9±0.3) 14 to 30 d after challenge. The degree of arthritis, the course of resolution of the joint and heart disease, and ability to recover spirochetes from OspA transgenic mice and nontransgenic littermates was similar. In addition, increasing the challenge dose of spirochetes to 107 did not result in noticeable differences in the course of Lyme borreliosis between the control and experimental transgenic mice. The course of Lyme borreliosis in OspB transgenic mice, on both the B6 and C3H background was also similar in the experimental and control mice (Table III) . 67 OspB transgenic mice were individually assessed in these studies. In OspB transgenic mice on a B6 background, arthritis was mild 0.5±0.3 at the 14-and 30-d time points and then resolved from 60 to 180 d. Somewhat fewer joints were affected with arthritis throughout the course of the study ( 14 to 180) days in OspB transgenic mice when compared with control animals; however, the differences were not statistically significant. In addition, carditis and the recovery of spirochetes from the transgenic and control mice was similar and increasing the challenge dose of spirochetes to 107 did not result in differences in the evolution of disease. As expected, arthritis was more severe in OspB transgenic mice on a C3H than a B6 background, and a greater number of the joints showed evidence of disease. Nevertheless, a similar course of infection and disease was noted within the control group as well.
Discussion
This study assesses the course of Lyme borreliosis in transgenic mice tolerant to OspA or B. Previous studies have implicated the immune responses to OspA and B in the pathogenesis of Lyme arthritis, both in animal models of disease and in patient populations (7, (10) (11) (12) (30) (31) (32) . For example, OspA and B selected timepoints between 14 and 180 d. Tissues (blood, spleen and bladder) were cultured in BSK medium for 2 wk and examined by darkfield microscopy for the presence of spirochetes. Mice from which B. burgdorferi were isolated from at least one tissue specimen were considered culture-positive. The knees, tibiotarsi and heart were examined microscopically for inflammation. The joint disease represents the tibiotarsi because these joints uniformly had more disease than the knees. Arthritis was graded (mean±standard deviation) on a scale from 0 to 3 in a double-blind fashion according to our published data. 'Resolving disease. Carditis was not graded. c Chronic, inactive, lesions. The results of control mice are indicated by parentheses. argued that these model systems cannot be directly extended to the human illness as the murine model only partially mimics the human infection. Indeed, the murine model most closely resembles acute arthritis and may not accurately depict chronic antibiotic-resistant human Lyme arthritis. Unfortunately, similar studies of the ablation of the OspA or B response in humans are not possible. Nonetheless, in many way the murine models have provided much useful information with regard to the immune response to B. burgdorferi that has been applicable to the human illness, most noticeably with respect to vaccine development and disease pathogenesis (18-20, 23, 33) . Indeed, it was initially suggested that the murine and human infections differed in that mice developed an early antibody response to OspA, whereas humans developed antibodies to OspA in the later stages of infection, if at all (6) . These initial murine studies used syringe challenge to inoculate the spirochetes, and subsequent studies using tick-mediated transmission in the murine model, show that the murine response to B. burgdorferi closely resembles the human response (6, 24) . Therefore, in as much as human infection is similar to murine Lyme borreliosis, these data strongly suggest that the OspA or B immune responses are not essential for the genesis of arthritis. This study, however, does not address the issue of the safety or potential limitation of an OspA-based vaccine in humans.
These studies also show that the immune responses to OspA or B are not individually required for the modulation and regression of disease in mice. Several groups have shown that scid mice develop severe persistent arthritis that does not undergo resolution-suggesting that the immune response that is generated during infection plays a role in the control of infection and the resolution of disease (16, 17) . The passive transfer of antiserum from mice infected with B. burgdorferi to infected scid mice can result in the modulation and regression of the disease-thereby transforming the course of disease in the scid mouse to the evolution of disease more commonly seen in the immunocompetent animals (S. Barthold, unpublished data). Moreover, arthritis in C3H mice begins to resolve as the animals develop an anti B. burgdorferi response, that-depending on the challenge dose of spirochetes-may or may not contain antibodies to OspA or B (24, 25) . Our studies, in OspA-or Btransgenic mice, show that the evolution of disease in the transgenic and nontransgenic littermates is similar, despite the inability of the transgenic mice to mount an antigen-specific response. Moreover, the data further suggests that the murine response to OspA, as in human Lyme borreliosis, occurs in the later stages of infection. This indicates that the immune response to OspA or B is not necessary for the regression of arthritis and carditis, and that the immune response, specifically antibodies, to other B. burgdorferi proteins can modulate disease.
In summary, we have successfully generated transgenic mice that are tolerant to B. burgdorferi OspA or B-the animals have a significantly diminished ability to respond to, or lack humoral and cellular immune responses to these specific antigens. We have shown that this ablated response does not alter the genesis of murine Lyme disease, including infection, arthritis and carditis, and suggests that the immune response to OspA or B is not singularly required to causes arthritis or carditis or result in the regression of disease in the B. burgdorferi infected mouse.
